Invivyd (NASDAQ:IVVD) Insider Sells $26,824.32 in Stock

Key Points

• Insider sale: Jill Andersen sold 37,256 Invivyd shares for $26,824.32 at an average price of $0.72 to cover tax withholding, reducing her stake by 10.59% to 314,480 shares. She also sold 30,706 shares the following day for $25,793.04.
• Stock and financial performance: Invivyd shares rose 17.2% to $0.87 in midday trading, but the company missed quarterly EPS expectations, reporting a $0.14 loss per share versus the $0.11 expected, alongside $14.29 million in revenue.
• Analyst outlook: The stock has a consensus rating of Hold from six analysts, with an average price target of $8.00; institutional investors own 70.36% of the company.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Jill Andersen sold 37,256 shares of Invivyd stock in a transaction on Monday, August 17th. The stock was sold at an average price of $0.72, for a total value of $26,824.32. Following the completion of the transaction, the insider owned 314,480 shares in the company, valued at $226,425.60. The trade was a 10.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Tuesday, August 18th, Jill Andersen sold 30,706 shares of Invivyd stock. The shares were sold at an average price of $0.84, for a total value of $25,793.04.

Invivyd Trading Up 17.2%

Shares of NASDAQ:IVVD traded up $0.13 during midday trading on Tuesday, reaching $0.87. The company had a trading volume of 7,732,095 shares, compared to its average volume of 3,061,089. Invivyd, Inc. has a 1-year low of $0.48 and a 1-year high of $3.07. The company has a fifty day simple moving average of $0.77 and a two-hundred day simple moving average of $1.23.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The business had revenue of $14.29 million during the quarter, compared to analysts' expectations of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. Sell-side analysts forecast that Invivyd, Inc. will post -0.52 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on IVVD. Weiss Ratings reissued a "sell (d-)" rating on shares of Invivyd in a research report on Friday, July 24th. Wall Street Zen lowered Invivyd from a "hold" rating to a "strong sell" rating in a research report on Saturday, May 16th. HC Wainwright reaffirmed a "buy" rating on shares of Invivyd in a research note on Tuesday. Finally, BTIG Research reiterated a "buy" rating on shares of Invivyd in a report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $8.00.

Institutional Investors Weigh In On Invivyd

Hedge funds have recently modified their holdings of the business. United Capital Financial Advisors LLC acquired a new position in Invivyd in the 2nd quarter valued at approximately $84,000. Bank of America Corp DE acquired a new position in shares of Invivyd in the second quarter valued at $311,000. Jupiter Topco LLC bought a new position in Invivyd in the second quarter worth $30,048,000. ADAR1 Capital Management LLC acquired a new stake in Invivyd during the second quarter worth $3,322,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Invivyd during the second quarter worth $52,000. 70.36% of the stock is owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source